Related Experiment Video
Updated: Sep 25, 2025

Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research
Published on: October 13, 2023
Two Children with Early-Onset Strokes and Intractable Epilepsy, Both with CACNA1A Mutations
Kristen N Bolte1, Melissa Assaf2, Tamara Zach2
1Midwestern University Arizona College of Osteopathic Medicine, Glendale, AZ, USA.
Insights
CACNA1A gene mutations can cause pediatric epilepsy, stroke, and developmental delays. Early identification of these CACNA1A mutations is crucial for effective medical management in affected children.
Area of Science:
- Genetics
- Neurology
- Pediatrics
Background:
- CACNA1A gene mutations are linked to various neurological disorders including epilepsy and migraine.
- Ischemic strokes are rarely associated with CACNA1A gene mutations.
Observation:
- Two unrelated pediatric patients presented with seizures, intractable epilepsy, ischemic stroke, and developmental delays.
- Whole exome sequencing identified distinct de novo pathogenic mutations in the CACNA1A gene in both patients.
Findings:
- The identified CACNA1A mutations, including a novel one, resulted in similar severe phenotypes in both unrelated children.
- This suggests a genotype-phenotype correlation where CACNA1A mutations can manifest as early-onset epilepsy and stroke.
Implications:
- Pediatric patients with ischemic stroke and seizures warrant evaluation for CACNA1A gene mutations.
- Prompt diagnosis of CACNA1A-related disorders facilitates targeted medical interventions and management strategies.
Abstract:
Background: Mutations in the CACNA1A gene have been associated phenotypically with Familial Hemiplegic Migraine Type 1, Episodic Ataxia Type 2, Idiopathic Generalized Epilepsy, and Developmental and Epileptic Encephalopathy 42. Only six cases have linked ischemic strokes to mutations in the CACNA1A gene. Summary of Cases: We describe two unrelated patients who were found to have different mutations of the CACNA1A gene, one being a novel mutation, as shown by whole exome sequencing. One presented with seizures at birth and the other with seizures at 17 months old, both eventually exhibiting intractable epilepsy, ischemic stroke, and developmental delays. Results: Whole exome sequencing demonstrated de novo pathogenic mutations in the CACNA1A gene, which both caused similar phenotypes in unrelated patients. Conclusion: Pediatric patients who present with ischemic stroke and a history of seizures should be evaluated for CACNA1A mutations, as prompt recognition can help providers facilitate appropriate medical management.
Related Concept Videos
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

